——Forging the Future Together

Overview

Beyond Isolation, Toward Integration
The fight against bladder cancer is a complex campaign. Just as Sun Tzu，a famous ancient Chinese military strategist， emphasized the strategic advantage of unity, we believe that overcoming drug resistance requires a collective effort. No single laboratory can hold all the answers. Therefore, our mission extends beyond the bench to building an open, collaborative ecosystem that connects laboratories, clinics, and the public, allowing knowledge to flow freely and accelerate discovery.

Laying the Foundation:
From Information to Understanding

"We believe the first step in defeating a challenge is to understand it together."


Demystifying the Science
We've translated the complexities of "ADC drugs" and "drug resistance" into accessible educational booklets and animated videos. This is more than just outreach; it's an open invitation for everyone to grasp the fundamentals, creating a common language for our community.
To enhance the scientific accuracy and accessibility of our educational booklet and science video, our team consulted with Dr. Gong, a senior urologist at Eastern Hepatobiliary Surgery Hospital. With his extensive clinical experience, Dr. Gong reviewed the medical content and provided valuable suggestions for presenting complex information in an engaging, easy-to-understand manner. This collaboration ensured our booklet and video maintains professional rigor while effectively communicating essential knowledge to patients and the general public. By incorporating expert insights, we have created a resource that successfully bridges the gap between specialized medical information and public understanding.
This educational booklet offers a concise guide to bladder cancer. It covers the fundamentals, contrasts traditional treatments with modern ADC therapy like RC48, and explains the "precision missile" mechanism of these drugs. Finally, it addresses the key challenge of drug resistance, outlining how cancer cells evade treatment. Using clear analogies and visuals, it empowers patients and the public withessential knowledge.

Our science video provides a comprehensive overview of bladder cancer, covering its epidemiology, risk factors, and current treatment options including ADC drugs. It highlights our research work in establishing drug-resistant bladder cancer models and identifying key resistance-related genes. The video aims to unravel the mechanisms behind drug resistance, offering new perspectives for future clinical therapies. Through accessible animation and clear explanations, it bridges scientific research with public understanding.

Bridging Bench and Bedside
Our interview with a leading urologist grounds our research in real-world clinical challenges. This ensures our community's discussions are focused on the most pressing patient needs and that scientific inquiry is guided by practical wisdom.

Key Takeaways:  The professor emphasized that overcoming resistance will inevitably rely on multi-modal combination strategies —integrating chemotherapy, immunotherapy, ADC drugs, and others—while highlighting the significant potential of artificial intelligence in understanding tumor evolution. This provides a crucial clinical perspective: isolated therapies are insufficient against cancer’s adaptive evolution.

Informed Directions:   The discussion illuminated innovative pathways for our research. The drug-resistant key genes we identified through multi-omics analysis hold clinical value if they can be targeted with existing or novel drugs. This inspires us to explore combination therapies based on specific resistance mechanisms —for instance, using targeted agents to inhibit resistance gene functions while combining them with ADC drugs or other treatments. Such an approach aims to outsmart rather than overpower resistance, truly enabling us to "anticipate the cancer’s next move."

Weaving the Network:
Sparking Innovation Through Dialogue

"We create platforms for dialogue, believing that the best ideas emerge at the intersection of diverse perspectives.

The Internal Forum
research.Our regular team meetings serve as an internal crucible for ideas. Here, data, setbacks, and hypotheses are shared openly, strengthening our research approach and fostering a culture of mutual support. Following the successful establishment of our bladder cancer drug resistance model, we partnered with a specialized biotechnology company to conduct whole genome sequencing. We then organized dedicated team meetings to thoroughly discuss the sequencing results. Team members from diverse disciplines collaborated to analyze genomic variation data, identifying key mutations potentially associated with drug resistance. Through this internal collaborative mechanism, we effectively advanced the understanding of bladder cancer resistance mechanisms, providing clear direction for subsequent
To enhance the scientific accuracy and accessibility of our educational booklet and science video, our team consulted with Dr. Gong, a senior urologist at Eastern Hepatobiliary Surgery Hospital. With his extensive clinical experience, Dr. Gong reviewed the medical content and provided valuable suggestions for presenting complex information in an engaging, easy-to-understand manner. This collaboration ensured our booklet and video maintains professional rigor while effectively communicating essential knowledge to patients and the general public. By incorporating expert insights, we have created a resource that successfully bridges the gap between specialized medical information and public understanding.
This educational booklet offers a concise guide to bladder cancer. It covers the fundamentals, contrasts traditional treatments with modern ADC therapy like RC48, and explains the "precision missile" mechanism of these drugs. Finally, it addresses the key challenge of drug resistance, outlining how cancer cells evade treatment. Using clear analogies and visuals, it empowers patients and the public withessential knowledge.

The External Window
Advancing Skills： At the 2025 iDEC Summer Symposium, our team gained valuable insights from Professor Zhang Shuailong of Beijing Institute of Technology regarding cutting-edge developments in micro-total analysis systems (µTAS), while also participating in specialized sessions on digital microfluidics (DMF). The technical advantages of these miniaturized platforms in single-cell analysis and high-throughput screening offer new perspectives for our bladder cancer drug resistance research. Moving forward, we plan to explore the application of µTAS and DMF technologies in constructing drug-resistant cell models. By utilizing precise droplet manipulation to automate the establishment of RC48 drug concentration gradients, we aim to significantly enhance screening efficiency. Additionally, the single-cell analysis capabilities will allow us to track the evolution of resistant clones, enabling dynamic analysis of resistance mechanisms. This technical exchange highlights the value of open science. By integrating these advanced engineering technologies, we are not only optimizing our research strategies but also pioneering an innovative "technology-sharing + disease-research" model, injecting new technical momentum into bladder cancer targeted therapy research.

Ideas exchange: We recently shared informational materials on bladder cancer with public health students at Fudan University, engaging in an in-depth discussion on disease risk factors, drug resistance mechanisms, and targeted therapies such as RC48. From a preventive medicine perspective, the students highlighted how epidemiological research could establish critical connections to bladder cancer drug resistance studies through a structured approach: "monitoring drug resistance incidence — identifying risk factors — validating molecular hypotheses."
They suggested that analyzing population-level patterns of drug resistance and its influencing factors may reveal new risk factors contributing to disease progression or treatment resistance. If correlated with the drug-resistant genes we have identified through experimental screening, these epidemiological findings could uncover potential links between macro-level factors—such as environmental exposures and lifestyle—and molecular-level mechanisms, offering new insights into resistance research.
This exchange underscored the value of interdisciplinary collaboration. By integrating population-based perspectives from public health with molecular-level exploratory research, we can build a comprehensive framework spanning from population prevention to precision medicine. Such collaborative approaches will open new pathways for understanding bladder cancer resistance mechanisms and optimizingtreatment strategies.

An Open Invitation:
Join Us in Shaping the Next Chapter

"This platform is not an endpoint; it is a hub for shared growth."

Starting Point
talents to our research findings.We have officially released our carefully produced science videos and educational brochures on our project's WeChat public account, while simultaneously sharing these resources on major social platforms including Xiaohongshu and Bilibili. This initiative aims to enhance public understanding of bladder cancer and its drug resistance mechanisms, while also hoping to draw attention from more innovative

We aspire to be like a stone cast into water, creating ripples that continuously expand - spreading knowledge and ideas to attract more collaborators in addressing the significant medical challenge of cancer drug resistance. Through persistent knowledge sharing and cross-disciplinary cooperation, we hope to gather collective wisdom to jointly overcome this crucial issue concerning human health.

A Call to Fellow Innovators
Our journey to combat bladder cancer drug resistance has been profoundly enriched by cross-disciplinary collaborations. We have engaged in meaningful dialogues with medical students across specialties, conducted insightful interviews with leading urologists from Changhai Hospital and oncologists from Fudan University Cancer Hospital. Beyond clinical medicine, we have bridged disciplines by collaborating with engineering specialists, exploring how technological innovation can empower medical research. Most recently, we hosted a productive online research exchange with clinical medicine students from Shandong University, Shandong First Medical University, and Changchun University of Chinese Medicine. This gathering of diverse perspectives has strengthened our conviction that complex challenges like drug resistance demand collective intelligence.
We now extend this invitation to you. Whether you bring expertise in clinical practice, biomedical engineering, computational biology, or simply share our passion for solving healthcare challenges, your unique perspective could be the key to unlocking new solutions. Together, we can pioneer innovative approaches to drug resistance - combining clinical insights with technological innovation, and traditional wisdom with cutting-edge science.
Join our growing community of innovators. Let's pool our expertise and creativity to develop the next generation of solutions for bladder cancer patients.

Epilogue

In the relentless evolution of cancer, openness and collaboration are our most powerful strategies. We choose not to work in isolation but to connect, collaborate, and co-create. We are convinced that the path to overcoming drug resistance lies within our collective intelligence.